Regulatory approval of anti-cancer drugs occurs typically after demonstration of clinical benefit in registration trials. Over the last 15 years, new drug development has focused on numerous mechanisms of action including conventional cytotoxic agents, inhibition of oncogenic signaling pathways, angiogenesis and immune modulation. In recent years, there has been substantial enthusiasm for immunotherapy agents [1–4]. However, the differential efficacy, safety, tolerability and price of these agents relative to other anti-neoplastic drugs are uncertain.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oW8f1A
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background Although pneumonia is a leading cause of death in New York City (NYC), limited data exist about the settings in which pneumonia ...
-
The Trojan War was over. The clever Greek Odysseus had tricked the enemy into bringing a colossal wooden horse within the walls of Troy. The...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1HDudvw via IFTTT
-
In The Advocate’s Women section, readers can find out the latest news and updates that are important to lesbian, bisexual, and transgender w...
-
Consulting to Finance: How to Network, Tell Your Story, Spin Your Resume, and Dominate Your Investment Banking and Private Equity Interviews...
-
ARE GEISHA PROSTITUTES? There has long been a misunderstanding in western society that Geisha are prostitutes. There are two main reasons fo...
-
Vol.30 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nItCSB via IFTTT
-
Overview (Based on a Mindtools article) Many people find that they learn best from , if they don’t reflect on their experience, and if they ...
-
Introduction. The conventional software development methodologies projects have failed to overcome the problem of volatility in the present ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου